Abstract: Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. In some embodiments, the PRP composition may be coated on one or more medical devices. The PRP composition may be delivered to an identified portion of the electrical conduction system of the heart affected and/or causing the arrhythmia to occur.

Abstract: Compositions for platelet rich plasma (PRP) are provided. Generally, these compositions comprise a higher concentration of platelets and white blood cells than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is described.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is disclosed.

Abstract: Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. The methods are useful for vascularizing tissue with a compromised blood supply, particularly cardiac tissue with a compromised blood supply due to heart attack or congestive heart failure.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to cardiac muscle for treatment of chronic dysfunction of cardiac muscle is disclosed.

Abstract: Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. In particular, a method of treating a cardiac tissue lesion is disclosed.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat acute dysfunction of cardiac muscle (heart attack) is disclosed.